Devonian Health Group Inc. (CVE:GSD – Get Free Report) traded down 23.5% on Saturday . The company traded as low as C$0.09 and last traded at C$0.13. 119,000 shares traded hands during trading, an increase of 588% from the average session volume of 17,288 shares. The stock had previously closed at C$0.17.
Devonian Health Group Trading Down 23.5%
The stock has a market cap of C$19.27 million, a P/E ratio of -4.64 and a beta of 0.67. The business’s 50 day simple moving average is C$0.16 and its two-hundred day simple moving average is C$0.17. The company has a quick ratio of 7.82, a current ratio of 1.07 and a debt-to-equity ratio of 16.36.
About Devonian Health Group
Devonian Health Group Inc engages in the development of botanical drugs. Its lead product candidate is Thykamine, completed Phase IIa clinical trial product for the treatment of ulcerative colitis and atopic dermatitis. The company also develops Pantoprazole Magnesium for the treatment of gastric; Cleo-35 for the treatment of hormonal acne in women; and value-added products for dermo-cosmetics.
See Also
- Five stocks we like better than Devonian Health Group
- Want to Profit on the Downtrend? Downtrends, Explained.
- 3 Overlooked Value Stocks Set to Surge as Rates Drop
- How to Short Nasdaq: An Easy-to-Follow Guide
- Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- After the Fed’s Rate Cut, PNC Could See a Mortgage Refinance Boom
Receive News & Ratings for Devonian Health Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Devonian Health Group and related companies with MarketBeat.com's FREE daily email newsletter.
